J&J Rybrevant Update Could Bode Positively For AstraZeneca’s Tagrisso

A Phase III trial of Rybrevant with lazertinib versus Tagrisso in first line EGFR-positive NSCLC is continuing after an interim analysis, surprising some investors who thought it might be stopped early for efficacy.

Question mark — Investors questioned the meaning behind a Rybrevant trial continuing to a final analysis • Source: Shutterstock

Johnson & Johnson’s ambition to position a combination regimen of the bispecific antibody Rybrevant (amivantamab) and EGFR inhibitor lazertinib as superior to AstraZeneca PLC’s Tagrisso (osimertinib) for certain types of non-small cell lung cancer (NSCLC) seems uncertain after the company said a Phase III clinical trial testing the two regimens head-to-head passed an interim analysis without stopping for efficacy or safety.

Management revealed during the company’s first quarter sales and earnings call on 18 April that the Phase III MARIPOSA trial...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

ProKidney Pins Hopes On Accelerated Approval For Rilparencel

09 Jul 2025

• By Alaric DeArment

After posting encouraging Phase II results, the company plans to meet with the US FDA about using data from an ongoing Phase III study for an accelerated approval.